Journal
JOURNAL OF VIRAL HEPATITIS
Volume 19, Issue 8, Pages 525-536Publisher
WILEY
DOI: 10.1111/j.1365-2893.2012.01634.x
Keywords
cyclophilin inhibitors; direct antiviral agent combination; HC; hepatitis C; interferon lambda; nitazoxanide; non-genotype 1; NS5A inhibitors; pegylated interferon; protease inhibitors; ribavirin; RNA polymerase inhibitors; silibinin; vitamin D
Ask authors/readers for more resources
. Worldwide, 5070 million subjects are infected with an hepatitis C virus (HCV) genotype 2, 3, 4, 5 or 6. In these patients, the combination of PEG-INF-a and ribavirin remains the currently approved standard-of-care treatment. The identification of different potential therapeutic targets in the HCV life cycle has led to the development of both direct antiviral agents (DAAs) and reagents targeting host functions essential for viral replication. DAAs comprise so far first-generation, second-wave and second-generation NS3/4A protease inhibitors (PIs), nucleos(t)ide (NIs) and non-nucleoside inhibitors of the NS5B RNA polymerase and NS5A complex inhibitors. The main host-protein-directed antiviral agents are cyclophilin inhibitors and silibinin. Whereas the launch of first-generation PIs was a major landmark in the management of genotype 1 (GT-1)-infected patients, these drugs are inactive in most non-GT-1-infected patients. Several of these and other drugs have now reached phase II and even phase III clinical stage development. The purpose of this article is to provide an overview of the clinical results recently reported for the treatment for non-GT-1 HCV infection with a focus on the most promising new compounds and combinations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available